Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

The present invention provides compounds, compositions, and methods for the treatment of prostate cancers, preferably, advanced prostate cancers. The subject invention also provides compounds, compositions, and methods for preventing/slowing down/reducing the progress and proliferation of prostate cancer cells. The subject invention further provides compounds, compositions, and methods for inhibiting DNA repair within cancer cells to slow tumor growth, preferably, by inhibiting BER capacity, including pol β and LIG I.